Your browser doesn't support javascript.
loading
Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay.
McGrail, D J; Pilié, P G; Rashid, N U; Voorwerk, L; Slagter, M; Kok, M; Jonasch, E; Khasraw, M; Heimberger, A B; Ueno, N T; Ferrarotto, R; Chang, J T; Lin, S-Y.
Afiliação
  • McGrail DJ; Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, USA; Lerner Research Institute, Cleveland Clinic, Cleveland. Electronic address: mcgraid@ccf.org.
  • Pilié PG; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Rashid NU; Department of Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, USA; Department of Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, USA.
  • Voorwerk L; Department of Division of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Slagter M; Department of Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Oncode Institute, Utrecht, the Netherlands.
  • Kok M; Department of Division of Tumor Biology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Jonasch E; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Khasraw M; Department of The Preston Robert Tisch Brain Tumor Center, Duke University, Durham, USA.
  • Heimberger AB; Department of Neurological Surgery, Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, USA.
  • Ueno NT; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Ferrarotto R; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Chang JT; Department of Integrative Biology and Pharmacology, The University of Texas Health Sciences Center at Houston, Houston, USA; Department of Bioinformatics and Computational Biology, Houston, USA.
  • Lin SY; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, USA.
Ann Oncol ; 33(11): 1204-1206, 2022 11.
Article em En | MEDLINE | ID: mdl-35926816
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares / Neoplasias Limite: Humans Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares / Neoplasias Limite: Humans Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article